Involvement of the CX3CL1 (fractalkine)/ CX3CR1 pathway in the pathogenesis of acute graft-versus-host disease

Journal of Leukocyte Biology

Volumn 97, Issue 2, 2015, Pages 227-235

  Brissot, Eolia ^a,b,c,d   Bossard, Celine ^e   Malard, Florent ^a,b,c,d   Braudeau, Cécile ^f   Chevallier, Patrice ^c,d   Guillaume, Thierry ^c,d   Delaunay, Jacques ^c,d   Josien, Régis ^f   Gregoire, Marc ^d   Gaugler, Beatrice ^g,h,i,j   Mohty, Mohamad ^a,b,c,d,e  

^a SORBONNE UNIVERSITÉ   (France)

^b INSERM   (France)

^c HÔTEL DIEU   (France)

^d CNRS   (France)

^e UNIVERSITÉ DE NANTES   (France)

^f NANTES UNIVERSITY HOSPITAL   (France)

^g RIGHT Interactions Hôte Greffon Tumeur Ingénierie Cellulaire et Génique   (France)

^h UNIVERSITÉ DE FRANCHE COMTÉ   (France)

ⁱ ETABLISSEMENT FRANÇAIS DU SANG   (France)

^j Plateforme de Biomonitoring   (France)

more..

Author keywords

Allogeneic transplant; Alloreactivity; Endothelium; Stem cell

Indexed keywords

CHEMOKINE RECEPTOR CX3CR1; CYCLOSPORIN; FRACTALKINE; MYCOPHENOLATE MOFETIL; CHEMOKINE RECEPTOR; CX3CL1 PROTEIN, HUMAN; CX3CR1 PROTEIN, HUMAN;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BIOPSY; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; ACUTE DISEASE; ALLOGRAFT; CD8+ T LYMPHOCYTE; EPITHELIUM CELL; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; MIDDLE AGED; MUCOSA; PATHOLOGY; TIME;

ACUTE DISEASE; ADULT; AGED; ALLOGRAFTS; CD8-POSITIVE T-LYMPHOCYTES; CHEMOKINE CX3CL1; EPITHELIAL CELLS; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MUCOUS MEMBRANE; RECEPTORS, CHEMOKINE; TIME FACTORS;

EID: 84925356235     PISSN: 07415400     EISSN: 19383673     Source Type: Journal    
DOI: 10.1189/jlb.5HI0714-325R     Document Type: Article

References (60)

1. Johnston, L. (2008) Acute graft-versus-host disease: differing risk with differing graft sources and conditioning intensity. Best Pract. Res. Clin. Haematol. 21, 177–192.
2. Baron, F., Labopin, M., Niederwieser, D., Vigouroux, S., Cornelissen, J. J., Malm, C., Vindelov, L. L., Blaise, D., Janssen, J. J., Petersen, E., Socié, G., Nagler, A., Rocha, V., Mohty, M. (2012) Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation. Leukemia 26, 2462–2468.
3. Choi, S. W., Stiff, P., Cooke, K., Ferrara, J. L., Braun, T., Kitko, C., Reddy, P., Yanik, G., Mineishi, S., Paczesny, S., Hanauer, D., Pawarode, A., Peres, E., Rodriguez, T., Smith, S., Levine, J. E. (2012) TNF-inhibition with etanercept for graft-versus-host disease prevention in high-risk HCT: lower TNFR1 levels correlate with better outcomes. Biol. Blood Marrow Transplant. 18, 1525–1532.
4. Ferrara, J. L., Levine, J. E., Reddy, P., Holler, E. (2009) Graft-versus-host disease. Lancet 373, 1550–1561.
5. Blazar, B. R., Murphy, W. J., Abedi, M. (2012) Advances in graft-versushost disease biology and therapy. Nat. Rev. Immunol. 12, 443–458.
6. Remberger, M., Ringden, O., Markling, L. (1995) TNF alpha levels are increased during bone marrow transplantation conditioning in patients who develop acute GVHD. Bone Marrow Transplant. 15, 99–104.
7. Choi, S. W., Kitko, C. L., Braun, T., Paczesny, S., Yanik, G., Mineishi, S., Krijanovski, O., Jones, D., Whitfield, J., Cooke, K., Hutchinson, R. J., Ferrara, J. L., Levine, J. E. (2008) Change in plasma tumor necrosis factor receptor 1 levels in the first week after myeloablative allogeneic transplantation correlates with severity and incidence of GVHD and survival. Blood 112, 1539–1542.
8. Dean, R. M., Fry, T., Mackall, C., Steinberg, S. M., Hakim, F., Fowler, D., Odom, J., Foley, J., Gress, R., Bishop, M. R. (2008) Association of serum interleukin-7 levels with the development of acute graft-versus-host disease. J. Clin. Oncol. 26, 5735–5741.
9. Thiant, S., Labalette, M., Trauet, J., Coiteux, V., de Berranger, E., Dessaint, J. P., Yakoub-Agha, I. (2011) Plasma levels of IL-7 and IL-15 after reduced intensity conditioned allo-SCT and relationship to acute GVHD. Bone Marrow Transplant. 46, 1374–1381.
10. Thiant, S., Yakoub-Agha, I., Magro, L., Trauet, J., Coiteux, V., Jouet, J. P., Dessaint, J. P., Labalette, M. (2010) Plasma levels of IL-7 and IL-15 in the first month after myeloablative BMT are predictive biomarkers of both acute GVHD and relapse. Bone Marrow Transplant. 45, 1546–1552.
11. Liu, D., Yan, C., Xu, L., Wang, Y., Han, W., Zhang, X., Liu, K., Huang, X. (2010) Diarrhea during the conditioning regimen is correlated with the occurrence of severe acute graft-versus-host disease through systemic release of inflammatory cytokines. Biol. Blood Marrow Transplant. 16, 1567–1575.
12. Paczesny, S., Krijanovski, O. I., Braun, T. M., Choi, S. W., Clouthier, S. G., Kuick, R., Misek, D. E., Cooke, K. R., Kitko, C. L., Weyand, A., Bickley, D., Jones, D., Whitfield, J., Reddy, P., Levine, J. E., Hanash, S. M., Ferrara, J. L. (2009) A biomarker panel for acute graft-versus-host disease. Blood 113, 273–278.
13. August, K. J., Chiang, K. Y., Bostick, R. M., Flanders, W. D., Waller, E. K., Langston, A., Worthington-White, D., Rowland, P., Moore, K. F., Khoury, H. J., Horan, J. T. (2011) Biomarkers of immune activation to screen for severe, acute GVHD. Bone Marrow Transplant. 46, 601–604.
14. Bacigalupo, A., Ballen, K., Rizzo, D., Giralt, S., Lazarus, H., Ho, V., Apperley, J., Slavin, S., Pasquini, M., Sandmaier, B. M., Barrett, J., Blaise, D., Lowski, R., Horowitz, M. (2009) Defining the intensity of conditioning regimens: working definitions. Biol. Blood Marrow Transplant. 15, 1628–1633.
15. Przepiorka, D., Weisdorf, D., Martin, P., Klingemann, H. G., Beatty, P., Hows, J., Thomas, E. D. (1995) 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 15, 825–828.
16. Epstein, R. J., McDonald, G. B., Sale, G. E., Shulman, H. M., Thomas, E. D. (1980) The diagnostic accuracy of the rectal biopsy in acute graft-versus-host disease: a prospective study of thirteen patients. Gastroenterology 78, 764–771.
17. Imai, T., Hieshima, K., Haskell, C., Baba, M., Nagira, M., Nishimura, M., Kakizaki, M., Takagi, S., Nomiyama, H., Schall, T. J., Yoshie, O. (1997) Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell 91, 521–530.
18. Goda, S., Imai, T., Yoshie, O., Yoneda, O., Inoue, H., Nagano, Y., Okazaki, T., Imai, H., Bloom, E. T., Domae, N., Umehara, H. (2000) CX3Cchemokine, fractalkine-enhanced adhesion of THP-1 cells to endothelial cells through integrin-dependent and -independent mechanisms. J. Immunol. 164, 4313–4320.
19. Fong, A. M., Robinson, L. A., Steeber, D. A., Tedder, T. F., Yoshie, O., Imai, T., Patel, D. D. (1998) Fractalkine and CX3CR1 mediate a novel mechanism of leukocyte capture, firm adhesion, and activation under physiologic flow. J. Exp. Med. 188, 1413–1419.
20. Cox, S. N., Sallustio, F., Serino, G., Loverre, A., Pesce, F., Gigante, M., Zaza, G., Stifanelli, P. F., Ancona, N., Schena, F. P. (2012) Activated innate immunity and the involvement of CX3CR1-fractalkine in promoting hematuria in patients with IgA nephropathy. Kidney Int. 82, 548–560.
21. Socié, G., Blazar, B. R. (2009) Acute graft-versus-host disease: from the bench to the bedside. Blood 114, 4327–4336.
22. Sackstein, R. (2006) A revision of Billingham’s tenets: the central role of lymphocyte migration in acute graft-versus-host disease. Biol. Blood Marrow Transplant. 12 (1 Suppl 1) 2–8.
23. Zhang, Y., Louboutin, J. P., Zhu, J., Rivera, A. J., Emerson, S. G. (2002) Preterminal host dendritic cells in irradiated mice prime CD8+ T cell-mediated acute graft-versus-host disease. J. Clin. Invest. 109, 1335–1344.
24. Shlomchik, W. D., Couzens, M. S., Tang, C. B., McNiff, J., Robert, M. E., Liu, J., Shlomchik, M. J., Emerson, S. G. (1999) Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 285, 412–415.
25. Matte, C. C., Liu, J., Cormier, J., Anderson, B. E., Athanasiadis, I., Jain, D., McNiff, J., Shlomchik, W. D. (2004) Donor APCs are required for maximal GVHD but not for GVL. Nat. Med. 10, 987–992.
26. Springer, T. A. (1994) Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 76, 301–314.
27. Hori, T., Naishiro, Y., Sohma, H., Suzuki, N., Hatakeyama, N., Yamamoto, M., Sonoda, T., Mizue, Y., Imai, K., Tsutsumi, H., Kokai, Y. (2008) CCL8 is a potential molecular candidate for the diagnosis of graft-versus-host disease. Blood 111, 4403–4412.
28. Piper, K. P., Horlock, C., Curnow, S. J., Arrazi, J., Nicholls, S., Mahendra, P., Craddock, C., Moss, P. A. (2007) CXCL10-CXCR3 interactions play an important role in the pathogenesis of acute graft-versus-host disease in the skin following allogeneic stem-cell transplantation. Blood 110, 3827–3832.
29. Reshef, R., Luger, S. M., Hexner, E. O., Loren, A. W., Frey, N. V., Nasta, S. D., Goldstein, S. C., Stadtmauer, E. A., Smith, J., Bailey, S., Mick, R., Heitjan, D. F., Emerson, S. G., Hoxie, J. A., Vonderheide, R. H., Porter, D. L. (2012) Blockade of lymphocyte chemotaxis in visceral graft-versushost disease. N. Engl. J. Med. 367, 135–145.
30. Garton, K. J., Gough, P. J., Blobel, C. P., Murphy, G., Greaves, D. R., Dempsey, P. J., Raines, E. W. (2001) Tumor necrosis factor-alphaconverting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1). J. Biol. Chem. 276, 37993–38001.
31. Hundhausen, C., Misztela, D., Berkhout, T. A., Broadway, N., Saftig, P., Reiss, K., Hartmann, D., Fahrenholz, F., Postina, R., Matthews, V., Kallen, K. J., Rose-John, S., Ludwig, A. (2003) The disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1-mediated cell-cell adhesion. Blood 102, 1186–1195.
32. Tsou, C. L., Haskell, C. A., Charo, I. F. (2001) Tumor necrosis factoralpha- converting enzyme mediates the inducible cleavage of fractalkine. J. Biol. Chem. 276, 44622–44626.
33. Bazan, J. F., Bacon, K. B., Hardiman, G., Wang, W., Soo, K., Rossi, D., Greaves, D. R., Zlotnik, A., Schall, T. J. (1997) A new class of membranebound chemokine with a CX3C motif. Nature 385, 640–644.
34. Garcia, G. E., Xia, Y., Chen, S., Wang, Y., Ye, R. D., Harrison, J. K., Bacon, K. B., Zerwes, H. G., Feng, L. (2000) NF-kappaB-dependent fractalkine induction in rat aortic endothelial cells stimulated by IL-1beta, TNF-alpha, and LPS. J. Leukoc. Biol. 67, 577–584.
35. Marchesi, F., Locatelli, M., Solinas, G., Erreni, M., Allavena, P., Mantovani, A. (2010) Role of CX3CR1/CX3CL1 axis in primary and secondary involvement of the nervous system by cancer. J. Neuroimmunol. 224, 39–44.
36. Nishimura, M., Umehara, H., Nakayama, T., Yoneda, O., Hieshima, K., Kakizaki, M., Dohmae, N., Yoshie, O., Imai, T. (2002) Dual functions of fractalkine/CX3C ligand 1 in trafficking of perforin+/granzyme B+ cytotoxic effector lymphocytes that are defined by CX3CR1 expression. J. Immunol. 168, 6173–6180.
37. Tong, N., Perry, S. W., Zhang, Q., James, H. J., Guo, H., Brooks, A., Bal, H., Kinnear, S. A., Fine, S., Epstein, L. G., Dairaghi, D., Schall, T. J., Gendelman, H. E., Dewhurst, S., Sharer, L. R., Gelbard, H. A. (2000) Neuronal fractalkine expression in HIV-1 encephalitis: roles for macrophage recruitment and neuroprotection in the central nervous system. J. Immunol. 164, 1333–1339.
38. Umehara, H., Bloom, E. T., Okazaki, T., Nagano, Y., Yoshie, O., Imai, T. (2004) Fractalkine in vascular biology: from basic research to clinical disease. Arterioscler. Thromb. Vasc. Biol. 24, 34–40.
39. D’Haese, J. G., Demir, I. E., Friess, H., Ceyhan, G. O. (2010) Fractalkine/CX3CR1: why a single chemokine-receptor duo bears a major and unique therapeutic potential. Expert Opin. Ther. Targets 14, 207–219.
40. Medina-Contreras, O., Geem, D., Laur, O., Williams, I. R., Lira, S. A., Nusrat, A., Parkos, C. A., Denning, T. L. (2011) CX3CR1 regulates intestinal macrophage homeostasis, bacterial translocation, and colitogenic Th17 responses in mice. J. Clin. Invest. 121, 4787–4795.
41. Mionnet, C., Buatois, V., Kanda, A., Milcent, V., Fleury, S., Lair, D., Langelot, M., Lacoeuille, Y., Hessel, E., Coffman, R., Magnan, A., Dombrowicz, D., Glaichenhaus, N., Julia, V. (2010) CX3CR1 is required for airway inflammation by promoting T helper cell survival and maintenance in inflamed lung. Nat. Med. 16, 1305–1312.
42. Broux, B., Pannemans, K., Zhang, X., Markovic-Plese, S., Broekmans, T., Eijnde, B. O., Van Wijmeersch, B., Somers, V., Geusens, P., van der Pol, S., van Horssen, J., Stinissen, P., Hellings, N. (2012) CX(3)CR1 drives cytotoxic CD4(+)CD28(2) T cells into the brain of multiple sclerosis patients. J. Autoimmun. 38, 10–19.
43. Tarrant, T. K., Liu, P., Rampersad, R. R., Esserman, D., Rothlein, L. R., Timoshchenko, R. G., McGinnis, M. W., Fitzhugh, D. J., Patel, D. D., Fong, A. M. (2012) Decreased Th17 and antigen-specific humoral responses in CX₃ CR1-deficient mice in the collagen-induced arthritis model. Arthritis Rheum. 64, 1379–1387.
44. Sasaki, M., Miyakoshi, M., Sato, Y., Nakanuma, Y. (2014) Chemokinechemokine receptor CCL2-CCR2 and CX3CL1-CX3CR1 axis may play a role in the aggravated inflammation in primary biliary cirrhosis. Dig. Dis. Sci. 59, 358–364.
45. El-Shazly, A., Berger, P., Girodet, P. O., Ousova, O., Fayon, M., Vernejoux, J. M., Marthan, R., Tunon-de-Lara, J. M. (2006) Fraktalkine produced by airway smooth muscle cells contributes to mast cell recruitment in asthma. J. Immunol. 176, 1860–1868.
46. Suzuki, F., Nanki, T., Imai, T., Kikuchi, H., Hirohata, S., Kohsaka, H., Miyasaka, N. (2005) Inhibition of CX3CL1 (fractalkine) improves experimental autoimmune myositis in SJL/J mice. J. Immunol. 175, 6987–6996.
47. Jamieson, W. L., Shimizu, S., D’Ambrosio, J. A., Meucci, O., Fatatis, A. (2008) CX3CR1 is expressed by prostate epithelial cells and androgens regulate the levels of CX3CL1/fractalkine in the bone marrow: potential role in prostate cancer bone tropism. Cancer Res. 68, 1715–1722.
48. Marchesi, F., Piemonti, L., Fedele, G., Destro, A., Roncalli, M., Albarello, L., Doglioni, C., Anselmo, A., Doni, A., Bianchi, P., Laghi, L., Malesci, A., Cervo, L., Malosio, M., Reni, M., Zerbi, A., Di Carlo, V., Mantovani, A., Allavena, P. (2008) The chemokine receptor CX3CR1 is involved in the neural tropism and malignant behavior of pancreatic ductal adenocarcinoma. Cancer Res. 68, 9060–9069.
49. Lu, J., Steeg, P. S., Price, J. E., Krishnamurthy, S., Mani, S. A., Reuben, J., Cristofanilli, M., Dontu, G., Bidaut, L., Valero, V., Hortobagyi, G. N., Yu, D. (2009) Breast cancer metastasis: challenges and opportunities. Cancer Res. 69, 4951–4953.
50. Corcione, A., Ferretti, E., Pistoia, V. (2012) CX3CL1/fractalkine is a novel regulator of normal and malignant human B cell function. J. Leukoc. Biol. 92, 51–58.
51. Ren, J., Hou, X. Y., Ma, S. H., Zhang, F. K., Zhen, J. H., Sun, L., Sun, Y. X., Hao, Y. L., Cheng, Y. F., Hou, M., Xu, C. G., Zhang, M. H., Peng, J. (2014) Elevated expression of CX3C chemokine receptor 1 mediates recruitment of T cells into bone marrow of patients with acquired aplastic anaemia. J. Intern. Med. 276, 512–524.
52. Murai, M., Yoneyama, H., Harada, A., Yi, Z., Vestergaard, C., Guo, B., Suzuki, K., Asakura, H., Matsushima, K. (1999) Active participation of CCR5(+)CD8(+) T lymphocytes in the pathogenesis of liver injury in graft-versus-host disease. J. Clin. Invest. 104, 49–57.
53. Palmer, L. A., Sale, G. E., Balogun, J. I., Li, D., Jones, D., Molldrem, J. J., Storb, R. F., Ma, Q. (2010) Chemokine receptor CCR5 mediates alloimmune responses in graft-versus-host disease. Biol. Blood Marrow Transplant. 16, 311–319.
54. Graubert, T. A., DiPersio, J. F., Russell, J. H., Ley, T. J. (1997) Perforin/ granzyme-dependent and independent mechanisms are both important for the development of graft-versus-host disease after murine bone marrow transplantation. J. Clin. Invest. 100, 904–911.
55. Blazar, B. R., Taylor, P. A., Vallera, D. A. (1997) CD4+ and CD8+ T cells each can utilize a perforin-dependent pathway to mediate lethal graftversus- host disease in major histocompatibility complex-disparate recipients. Transplantation 64, 571–576.
56. Schmaltz, C., Alpdogan, O., Horndasch, K. J., Muriglan, S. J., Kappel, B. J., Teshima, T., Ferrara, J. L., Burakoff, S. J., van den Brink, M. R. (2001) Differential use of Fas ligand and perforin cytotoxic pathways by donor T cells in graft-versus-host disease and graft-versus-leukemia effect. Blood 97, 2886–2895.
57. Hsieh, M. H., Korngold, R. (2000) Differential use of FasL- and perforinmediated cytolytic mechanisms by T-cell subsets involved in graft-versusmyeloid leukemia responses. Blood 96, 1047–1055.
58. Fraticelli, P., Sironi, M., Bianchi, G., D’Ambrosio, D., Albanesi, C., Stoppacciaro, A., Chieppa, M., Allavena, P., Ruco, L., Girolomoni, G., Sinigaglia, F., Vecchi, A., Mantovani, A. (2001) Fractalkine (CX3CL1) as an amplification circuit of polarized Th1 responses. J. Clin. Invest. 107, 1173–1181.
59. Teshima, T. (2011) Th1 and Th17 join forces for acute GVHD. Blood 118, 4765–4767.
60. Ferrara, J. L., Harris, A. C., Greenson, J. K., Braun, T. M., Holler, E., Teshima, T., Levine, J. E., Choi, S. W., Huber, E., Landfried, K., Akashi, K., Vander Lugt, M., Reddy, P., Chin, A., Zhang, Q., Hanash, S., Paczesny, S. (2011) Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease. Blood 118, 6702–6708.